At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Longitudinal Study to Identify IBS Phenotypes Using Fecal Microbiota and Hydrogen Breath Testing
In Brief
A Phase 4 clinical trial evaluating Rifaximin 550 MG and Low FODMAP Diet for Irritable Bowel Syndrome. Completed, enrolled 74 participants across 1 site.
Detailed Summary
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a highly prevalent but poorly understood condition with limited treatment options. Current therapies, including a nonabsorbable antibiotic rifaximin or diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP), show efficacy in 50% or less of patients. In this proposal, participants with IBS-D will be randomized to receive either rifaximin or low FODMAP dietary intervention.
Study Details
Timeline
Interventions
Rifaximin 550 mg three times daily for 14 days
Low FODMAP dietary intervention for 4 weeks